Journal article
Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen
Cancer chemotherapy and pharmacology, Vol.34(3), pp.261-265
1994
DOI: 10.1007/BF00685087
PMID: 8004761
Abstract
A phase I and pharmacokinetics study was carried out of floxuridine (FdUrd) modulated by leucovorin (LV) given on the Roswell Park regimen (LV given at 500 mg/m2 by 2-h infusion and FdUrd given by i.v. push at 1 h after the start of LV infusion, treatment being given weekly×6). The dose-limiting toxicity was diarrhea; the MTD and recommended dose for phase II studies was 1,650 mg/m2 per week of FdUrd. The dose-response curve was steep, with 3/3 patients treated at a dose of 1,750 mg/m2 developing grade IV diarrhea. With this schedule there was no significant mucositis. Pharmacokinetic parameters showed very wide interpatient variability. Plasma decay was biphasic with a t1/2β of approximately 2 h. Plasma clearance was high (>200 l h-1). No correlation between pharmacokinetic parameters and toxicity could be identified. © 1994 Springer-Verlag.
Details
- Title: Subtitle
- Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen
- Creators
- Patrick J. Creaven - Roswell Park Cancer InstituteYoucef M. Rustum - Roswell Park Cancer InstituteNicholas J. Petrelli - Roswell Park Cancer InstituteNeal J. Meropol - Roswell Park Cancer InstituteDerek Raghavan - Roswell Park Cancer InstituteMiguel Rodriguez-Bigas - Roswell Park Cancer InstituteEllis G. Levine - Roswell Park Cancer InstituteCheryl Frank - Roswell Park Cancer InstituteSzilvia Udvary-Nagy - Roswell Park Cancer InstituteApril Proefrock - Roswell Park Cancer Institute
- Resource Type
- Journal article
- Publication Details
- Cancer chemotherapy and pharmacology, Vol.34(3), pp.261-265
- DOI
- 10.1007/BF00685087
- PMID
- 8004761
- ISSN
- 0344-5704
- eISSN
- 1432-0843
- Language
- English
- Date published
- 1994
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359933702771
Metrics
7 Record Views